Role of FMS-Like Tyrosine Kinase 3 (FLT3) Inhibitors in a Patient With T/Myeloid Acute Leukemia With an FLT3 Mutation
Cureus · 23.03.2026
DOI: 10.7759/cureus.105695 ↗Kurz gefasst
Fallbericht in der Zeitschrift Cureus, erschienen am 23.03.2026. Verfasst von Nicholas Elias und 3 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine, Henry Ford St. John Hospital, Detroit, USA. Die Arbeit nennt 6 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Internal Medicine, Henry Ford St. John Hospital, Detroit, USA.
- Hematology/Oncology, Henry Ford St. John Hospital, Detroit, USA.
Zitieren
APA
Elias, N., Siddiqui, A., Bazzi, T., & Lebovic, D. (2026). Role of FMS-Like Tyrosine Kinase 3 (FLT3) Inhibitors in a Patient With T/Myeloid Acute Leukemia With an FLT3 Mutation. Cureus. https://doi.org/10.7759/cureus.105695
Vancouver
Elias N, Siddiqui A, Bazzi T, Lebovic D. Role of FMS-Like Tyrosine Kinase 3 (FLT3) Inhibitors in a Patient With T/Myeloid Acute Leukemia With an FLT3 Mutation. Cureus. 2026. doi:10.7759/cureus.105695
BibTeX
@article{Elias2026,
author = {Elias, Nicholas and Siddiqui, Ahsun and Bazzi, Talal and Lebovic, Daniel},
title = {Role of FMS-Like Tyrosine Kinase 3 (FLT3) Inhibitors in a Patient With T/Myeloid Acute Leukemia With an FLT3 Mutation},
journal = {Cureus},
year = {2026},
doi = {10.7759/cureus.105695}
}
EUVIMED